GlassScriptPhysician profile
Reena P Jogi
NPI 1538299862
$23,116.61
in general payments reported to CMS, 2019-2025
38 companies · $4,578 in 2025
The $4,578 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,427 · 2020: $1,596 · 2021: $2,493 · 2022: $2,987 · 2023: $5,348 · 2024: $3,688 · 2025: $4,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,976.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Education | $386.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,563.46 | 2019-2025 | |
| Janssen Biotech, INC. | $2,467.65 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $2,186.49 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,385.78 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $1,215.77 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,214.37 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $1,074.73 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $978.98 | 2023-2025 | Zoryve |
| Genzyme Corporation | $894.39 | 2019-2025 | |
| Revance Therapeutics, INC. | $850.39 | 2024-2025 | Daxxify |
| Incyte Corporation | $846.15 | 2021-2025 | Opzelura |
| Pfizer INC. | $794.06 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $776.36 | 2019-2025 | Ilumya |
| Amgen INC. | $643.64 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $586.70 | 2019-2025 | Adbry, Anzupgo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $528.12 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $445.57 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $261.12 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Hill Dermaceuticals, INC. | $201.09 | 2020-2021 | |
| Almirall LLC | $189.62 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $175.85 | 2019-2020 | |
| Organon LLC | $140.82 | 2025 | Vtama |
| Allergan, INC. | $130.88 | 2019-2022 | |
| Epi Health, LLC | $100.62 | 2021-2022 | |
| Dermira, INC. | $83.16 | 2019-2021 | |
| Encore Dermatology INC. | $66.05 | 2019 | |
| Botanix Sb INC | $62.53 | 2025 | Sofdra |
| Journey Medical Corporation | $53.22 | 2022-2023 | |
| Vyne Pharmaceuticals INC. | $45.70 | 2020 | |
| Biofrontera INC. | $22.56 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.06 | 2024 | Spevigo |
| Genentech USA, INC. | $19.99 | 2019 | |
| Promius Pharma LLC | $19.87 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.76 | 2019 | |
| Mission Pharmacal Company | $14.42 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.20 | 2019 | |
| Celgene Corporation | $13.66 | 2019 | |
| Merck Sharp & Dohme LLC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Jogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.